Altogether, tumor-derived OPN and its engagement with CD44 on CD8+ T cells present an additional checkpoint that dampens T-cell activation, and perhaps an exploitable vulnerability, that confers immunotherapy resistance (82). This evidence concerns the gene CD8A and neoplasm.